Gene expression signatures for colorectal cancer microsatellite status and HNPCC

被引:65
作者
Kruhoffer, M
Jensen, JL
Laiho, P
Dyrskjot, L
Salovaara, R
Arango, D
Birkenkamp-Demtroder, K
Sorensen, FB
Christensen, LL
Buhl, L
Mecklin, JP
Järvinen, H
Thykjaer, T
Wikman, FP
Bech-Knudsen, F
Juhola, M
Nupponen, NN
Laurberg, S
Andersen, CL
Aaltonen, LA
Orntoft, TF
机构
[1] Aarhus Univ Hosp, Dept Clin Biochem, Mol Diagnost Lab, DK-8200 Aarhus, Denmark
[2] Univ Aarhus, Dept Stat, Aarhus, Denmark
[3] Univ Helsinki, Dept Med Genet, Haartman Inst, Helsinki, Finland
[4] Aarhus Univ Hosp, Inst Pathol, DK-8200 Aarhus, Denmark
[5] Jyvaskyla Cent Hosp, Dept Pathol, Helsinki, Finland
[6] Univ Helsinki, Haartman Inst, Univ Cent Hosp, Helsinki, Finland
[7] AROS Appl Biotechnol ApS, Res Pk Skejby, Aarhus, Denmark
[8] Aarhus Univ Hosp, Dept Surg, DK-8200 Aarhus, Denmark
关键词
colon cancer; gene expression; microsatellite instability; HNPCC;
D O I
10.1038/sj.bjc.6602621
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The majority of microsatellite instable (MSI) colorectal cancers are sporadic, but a subset belongs to the syndrome hereditary nonpolyposis colorectal cancer (HNPCC). Microsatellite instability is caused by dysfunction of the mismatch repair (MMR) system that leads to a mutator phenotype, and MSI is correlated to prognosis and response to chemotherapy. Gene expression signatures as predictive markers are being developed for many cancers, and the identification of a signature for MMR deficiency would be of interest both clinically and biologically. To address this issue, we profiled the gene expression of 101 stage II and III colorectal cancers ( 34 MSI, 67 microsatellite stable (MSS)) using high-density oligonucleotide microarrays. From these data, we constructed a nine-gene signature capable of separating the mismatch repair proficient and deficient tumours. Subsequently, we demonstrated the robustness of the signature by transferring it to a real-time RT-PCR platform. Using this platform, the signature was validated on an independent test set consisting of 47 tumours ( 10 MSI, 37 MSS), of which 45 were correctly classified. In a second step, we constructed a signature capable of separating MMR-deficient tumours into sporadic MSI and HNPCC cases, and validated this by a mathematical cross-validation approach. The demonstration that this two-step classification approach can identify MSI as well as HNPCC cases merits further gene expression studies to identify prognostic signatures.
引用
收藏
页码:2240 / 2248
页数:9
相关论文
共 36 条
  • [1] Allegra CJ, 2003, NEW ENGL J MED, V349, P1774
  • [2] Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays
    Alon, U
    Barkai, N
    Notterman, DA
    Gish, K
    Ybarra, S
    Mack, D
    Levine, AJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (12) : 6745 - 6750
  • [3] Normalization of real-time quantitative reverse transcription-PCR data: A model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets
    Andersen, CL
    Jensen, JL
    Orntoft, TF
    [J]. CANCER RESEARCH, 2004, 64 (15) : 5245 - 5250
  • [4] Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity
    Banerjea, Ayan
    Ahmed, Shafi
    Hands, Rebecca E.
    Huang, Fei
    Han, Xia
    Shaw, Peter M.
    Feakins, Roger
    Bustin, Stephen A.
    Dorudi, Sina
    [J]. MOLECULAR CANCER, 2004, 3 (1)
  • [5] Birkenkamp-Demtroder K, 2002, CANCER RES, V62, P4352
  • [6] A comparison of normalization methods for high density oligonucleotide array data based on variance and bias
    Bolstad, BM
    Irizarry, RA
    Åstrand, M
    Speed, TP
    [J]. BIOINFORMATICS, 2003, 19 (02) : 185 - 193
  • [7] Hereditary nonpolyposis colorectal cancer - molecular basis
    Brezden-Masley, C
    Aronson, MD
    Bapat, B
    Pollett, A
    Gryfe, R
    Reston, M
    Gallinger, S
    [J]. SURGERY, 2003, 134 (01) : 29 - 33
  • [8] Bubb VJ, 1996, ONCOGENE, V12, P2641
  • [9] Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer
    Cappel, WHDN
    Meulenbeld, HJ
    Kleibeuker, JH
    Nagengast, FM
    Menko, FH
    Griffioen, G
    Cats, A
    Morreau, H
    Gelderblom, H
    Vasen, HFA
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2004, 109 (03) : 468 - 471
  • [10] Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
    Cunningham, D
    Pyrhönen, S
    James, RD
    Punt, CJA
    Hickish, TF
    Heikkila, R
    Johannesen, TB
    Starkhammar, H
    Topham, CA
    Awad, L
    Jacques, C
    Herait, P
    [J]. LANCET, 1998, 352 (9138) : 1413 - 1418